title: Certolizumab pegol.
abstract: In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies.
authors.forename: Gil Y
authors.initials: GY
authors.lastname: Melmed
authors.forename: Stephan R
authors.initials: SR
authors.lastname: Targan
authors.forename: Uma
authors.initials: U
authors.lastname: Yasothan
authors.forename: Delphine
authors.initials: D
authors.lastname: Hanicq
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D003424:Crohn Disease / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol